Abstract
Zerumbet ginger extract (ZGE) shows strong anticancer potential and enhances doxorubicin (DOX) efficacy against breast cancer while reducing its systemic toxicity. GC-MS identified zerumbone as a key bioactive. ZGE inhibited 4 T1 cell growth and tumor progression in mice and improved antioxidant activity. Combined ZGE + DOX treatment boosted antitumor effects and alleviated DOX-induced cardiotoxicity, hepatotoxicity, and nephrotoxicity, as reflected in biochemical markers. Mechanistically, ZGE suppressed TRPM2 and calcium signaling, promoting ROS-mediated apoptosis. These findings support ZGE as a promising adjuvant in breast cancer therapy.